BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Messina S, Sframeli M. New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges. J Clin Med 2020;9:E2222. [PMID: 32668756 DOI: 10.3390/jcm9072222] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 18.3] [Reference Citation Analysis]
Number Citing Articles
1 Bhachawat S, Shriram E, Srinivasan K, Hu YC. Leveraging Computational Intelligence Techniques for Diagnosing Degenerative Nerve Diseases: A Comprehensive Review, Open Challenges, and Future Research Directions. Diagnostics (Basel) 2023;13. [PMID: 36673100 DOI: 10.3390/diagnostics13020288] [Reference Citation Analysis]
2 Lejman J, Panuciak K, Nowicka E, Mastalerczyk A, Wojciechowska K, Lejman M. Gene Therapy in ALS and SMA: Advances, Challenges and Perspectives. Int J Mol Sci 2023;24. [PMID: 36674643 DOI: 10.3390/ijms24021130] [Reference Citation Analysis]
3 Sagerer E, Wirner C, Schoser B, Wenninger S. Nociceptive pain in adult patients with 5q-spinal muscular atrophy type 3: a cross-sectional clinical study. J Neurol 2023;270:250-61. [PMID: 36036285 DOI: 10.1007/s00415-022-11351-0] [Reference Citation Analysis]
4 Vincent-Genod D, Rippert P, Coton J, Le Goff L, Barriere A, Berruyer A, Bernard M, Garde C, Gutierrez-Garcia M, Gilabert S, Gomes-Lisboade-Souza A, Daron A, Servais L, Thomann G, Vuillerot C. Scoring People With Spinal Muscular Atrophy on the Motor Function Measure Using the Microsoft Kinect. Pediatr Phys Ther 2023;35:36-41. [PMID: 36288197 DOI: 10.1097/PEP.0000000000000968] [Reference Citation Analysis]
5 Shpilyukova YA, Illarioshkin SN. Adult spinal muscular atrophy: problems of early diagnosis. Neuromuscular Diseases 2022;12:37-45. [DOI: 10.17650/2222-8721-2022-12-4-37-45] [Reference Citation Analysis]
6 Tkaczuk M, Zakrzewski DM, Król M, Zawadzka M, Waszak PM, Mazurkiewicz-Bełdzińska M. Social Media as a Source of Knowledge about Gene Therapy for Spinal Muscular Atrophy. Healthcare (Basel) 2022;10. [PMID: 36553969 DOI: 10.3390/healthcare10122445] [Reference Citation Analysis]
7 Wang W, Feng Y, Long Q, Chen F, Chen Y, Ma M, Mao S. A comparative analysis of body composition assessment by BIA and DXA in children with type II and III spinal muscular atrophy. Front Neurol 2022;13. [DOI: 10.3389/fneur.2022.1034894] [Reference Citation Analysis]
8 A. Devade O, D. Londhe R, M. Meshram N. Review on Spinal Muscular Atrophy. RJPPD 2022. [DOI: 10.52711/2321-5836.2022.00042] [Reference Citation Analysis]
9 Belter L, Mazzella A, O’brien S, Jarecki J. Knowledge of genetic test results among caregivers and individuals with spinal muscular atrophy. PLoS ONE 2022;17:e0276756. [DOI: 10.1371/journal.pone.0276756] [Reference Citation Analysis]
10 Matteson J, Wu CH, Mathur D, Tang H, Sciortino S, Feuchtbaum L, Bishop T, Sharma SC, Neogi P, Fitzgibbon I, Olney RS. California’s experience with SMA newborn screening: A successful path to early intervention. JND 2022;9:777-785. [DOI: 10.3233/jnd-221561] [Reference Citation Analysis]
11 Santos F, Capela AM, Mateus F, Nóbrega-Pereira S, Bernardes de Jesus B. Non-coding antisense transcripts: fine regulation of gene expression in cancer. Comput Struct Biotechnol J 2022;20:5652-60. [PMID: 36284703 DOI: 10.1016/j.csbj.2022.10.009] [Reference Citation Analysis]
12 Tam PKH, Wong KKY, Atala A, Giobbe GG, Booth C, Gruber PJ, Monone M, Rafii S, Rando TA, Vacanti J, Comer CD, Elvassore N, Grikscheit T, de Coppi P. Regenerative medicine: postnatal approaches. The Lancet Child & Adolescent Health 2022;6:654-666. [DOI: 10.1016/s2352-4642(22)00193-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Qiu J, Wu L, Qu R, Jiang T, Bai J, Sheng L, Feng P, Sun J. History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy. Front Cell Neurosci 2022;16:942976. [DOI: 10.3389/fncel.2022.942976] [Reference Citation Analysis]
14 Panagiotou P, Kanaka-gantenbein C, Kaditis AG. Changes in Ventilatory Support Requirements of Spinal Muscular Atrophy (SMA) Patients Post Gene-Based Therapies. Children 2022;9:1207. [DOI: 10.3390/children9081207] [Reference Citation Analysis]
15 Hickox AE, Valero MD, McLaughlin JT, Robinson GS, Wellman JA, McKenna MJ, Sewell WF, Simons EJ. Genetic Medicine for Hearing Loss: OTOF as Exemplar. J Am Acad Audiol 2021;32:646-53. [PMID: 35609591 DOI: 10.1055/s-0041-1730410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Khayrullina G, Alipio-Gloria ZA, Deguise MO, Gagnon S, Chehade L, Stinson M, Belous N, Bergman EM, Lischka FW, Rotty J, Dalgard CL, Kothary R, Johnson KA, Burnett BG. Survival motor neuron protein deficiency alters microglia reactivity. Glia 2022. [PMID: 35373853 DOI: 10.1002/glia.24177] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
17 Paik J. Risdiplam: A Review in Spinal Muscular Atrophy. CNS Drugs. [DOI: 10.1007/s40263-022-00910-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Saposnik G, Díaz-abós P, Sánchez-menéndez V, Álvarez C, Terzaghi M, Maurino J, Brañas-pampillón M, Málaga I. Therapeutic decisions under uncertainty for spinal muscular atrophy: The DECISIONS-SMA study protocol. PLoS ONE 2022;17:e0264006. [DOI: 10.1371/journal.pone.0264006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Artemyeva SB, Papina YO, Shidlovskaya OA, Monakhova AV, Vlodavets DV. Experience of using gene replacement therapy with Zolgensma® (onasemnogene abeparvovec) in real clinical practice in Russia. Neuromuscular Diseases 2022;12:29-38. [DOI: 10.17650/2222-8721-2022-12-1-29-38] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 MacCannell D, Berger Z, Kirschner J, Mercuri E, Farrar MA, Iannaccone ST, Kuntz NL, Finkel RS, Valente M, Muntoni F. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model. CNS Drugs 2022. [PMID: 35080757 DOI: 10.1007/s40263-022-00899-0] [Reference Citation Analysis]
21 Sarv S, Kahre T, Vaidla E, Pajusalu S, Muru K, Põder H, Gross-Paju K, Ütt S, Žordania R, Talvik I, Õiglane-Shlik E, Muhu K, Õunap K. The Birth Prevalence of Spinal Muscular Atrophy: A Population Specific Approach in Estonia. Front Genet 2021;12:796862. [PMID: 35003227 DOI: 10.3389/fgene.2021.796862] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Urciuolo A, Easler M, Elvassore N. Recapitulating human skeletal muscle in vitro. Recapitulating the Stem Cell Niche Ex Vivo 2022. [DOI: 10.1016/bs.asn.2021.10.003] [Reference Citation Analysis]
23 Filatov EU, Sergeenko OM, Savin DM, Ochirova PV, Ryabykh SO. FRONTAL AND SAGITTAL PATTERNS OF NEUROMUSCULAR SPINAL DEFORMITIES BASED ON NOSOLOGICAL PROFILE. Coluna/Columna 2022;21. [DOI: 10.1590/s1808-185120222104262160] [Reference Citation Analysis]
24 Komatsu H. Innovative Therapeutic Approaches for Huntington's Disease: From Nucleic Acids to GPCR-Targeting Small Molecules. Front Cell Neurosci 2021;15:785703. [PMID: 34899193 DOI: 10.3389/fncel.2021.785703] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
25 Kakazu J, Walker NL, Babin KC, Trettin KA, Lee C, Sutker PB, Kaye AM, Kaye AD. Risdiplam for the Use of Spinal Muscular Atrophy. Orthop Rev (Pavia) 2021;13:25579. [PMID: 34745484 DOI: 10.52965/001c.25579] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
26 Schloss N, Wirth B, Kruse T, Lehmann HC, Wunderlich G. Diagnostik und Therapie der spinalen Muskelatrophie (SMA) bei Erwachsenen. DGNeurologie 2021;4:501-515. [DOI: 10.1007/s42451-021-00386-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Leonard SJ. Reproductive genetic screening for information: evolving paradigms? J Perinat Med 2021;49:998-1002. [PMID: 34448384 DOI: 10.1515/jpm-2021-0353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Nicole S, Lory P. New Challenges Resulting From the Loss of Function of Nav1.4 in Neuromuscular Diseases. Front Pharmacol 2021;12:751095. [PMID: 34671263 DOI: 10.3389/fphar.2021.751095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Vlodavets DV, Ganina NV, Ilina ES, Kokorina AA, Kuzenkova LM, Sapego EY, Smirnov DS, Shevtsova YA, Saulina AV, Petrov AN, Zolkin NA, Linkova YN, Zinkina-orikhan AV. Retrospective analysis of the natural history of type 1 spinal muscular atrophy in children. Ross vestn perinatol pediatr 2021;66:64-73. [DOI: 10.21508/1027-4065-2021-66-4-64-73] [Reference Citation Analysis]
30 Beaufils M, Travard L, Rendu J, Marty I. Therapies for RYR1-Related Myopathies: Where We Stand and the Perspectives. Curr Pharm Des 2021. [PMID: 34514983 DOI: 10.2174/1389201022666210910102516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Lejman J, Zieliński G, Gawda P, Lejman M. Alternative Splicing Role in New Therapies of Spinal Muscular Atrophy. Genes (Basel) 2021;12:1346. [PMID: 34573328 DOI: 10.3390/genes12091346] [Reference Citation Analysis]
32 Krause K, Wulf M, Sommer P, Barkovits K, Vorgerd M, Marcus K, Eggers B. CSF Diagnostics: A Potentially Valuable Tool in Neurodegenerative and Inflammatory Disorders Involving Motor Neurons: A Review. Diagnostics (Basel) 2021;11:1522. [PMID: 34573864 DOI: 10.3390/diagnostics11091522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Krappinger JC, Bonstingl L, Pansy K, Sallinger K, Wreglesworth NI, Grinninger L, Deutsch A, El-Heliebi A, Kroneis T, Mcfarlane RJ, Sensen CW, Feichtinger J. Non-coding Natural Antisense Transcripts: Analysis and Application. J Biotechnol 2021:S0168-1656(21)00210-8. [PMID: 34371054 DOI: 10.1016/j.jbiotec.2021.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Slayter J, Hodgkinson V, Lounsberry J, Brais B, Chapman K, Genge A, Izenberg A, Johnston W, Lochmüller H, O'Ferrall E, Pfeffer G, Plamondon S, Rodrigue X, Schellenberg K, Shoesmith C, Stables C, Taillon M, Warman-Chardon J, Korngut L, O'Connell C. A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit: Results of a National Consensus using a Modified Delphi Method. J Neuromuscul Dis 2021;8:579-88. [PMID: 33867362 DOI: 10.3233/JND-200617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Baker MW, Mochal ST, Dawe SJ, Wiberley-Bradford AE, Cogley MF, Zeitler BR, Piro ZD, Harmelink MM, Kwon JM. Newborn screening for spinal muscular atrophy: The Wisconsin first year experience. Neuromuscul Disord 2021:S0960-8966(21)00585-X. [PMID: 35120759 DOI: 10.1016/j.nmd.2021.07.398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Thibault PA, Ganesan A, Kalyaanamoorthy S, Clarke JWE, Salapa HE, Levin MC. hnRNP A/B Proteins: An Encyclopedic Assessment of Their Roles in Homeostasis and Disease. Biology (Basel) 2021;10:712. [PMID: 34439945 DOI: 10.3390/biology10080712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
37 Bischof M, Lorenzi M, Lee J, Druyts E, Balijepalli C, Dabbous O. Matching-adjusted indirect treatment comparison of onasemnogene abeparvovec and nusinersen for the treatment of symptomatic patients with spinal muscular atrophy type 1. Curr Med Res Opin 2021;:1-12. [PMID: 34236007 DOI: 10.1080/03007995.2021.1947216] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Corsello A, Scatigno L, Pascuzzi MC, Calcaterra V, Dilillo D, Vizzuso S, Pelizzo G, Zoia E, Mandelli A, Govoni A, Bosetti A, Francavilla R, Indrio F, Fabiano V, Zuccotti GV, Verduci E. Nutritional, Gastrointestinal and Endo-Metabolic Challenges in the Management of Children with Spinal Muscular Atrophy Type 1. Nutrients 2021;13:2400. [PMID: 34371910 DOI: 10.3390/nu13072400] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
39 Klotz J, Tesi Rocha C, Dunaway Young S, Duong T, Buu M, Sampson J, Day JW. Advances in the Therapy of Spinal Muscular Atrophy. J Pediatr 2021;236:13-20.e1. [PMID: 34197889 DOI: 10.1016/j.jpeds.2021.06.033] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
40 Xiao L, Chiang J, Amin R. Paradigm shift in the era of disease-modifying therapies for Spinal Muscular Atrophy type 1: respiratory challenges and opportunities. Sleep Med 2021:S1389-9457(21)00357-9. [PMID: 34253462 DOI: 10.1016/j.sleep.2021.06.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Gandhi G, Abdullah S, Foead AI, Yeo WWY. The potential role of miRNA therapies in spinal muscle atrophy. J Neurol Sci 2021;427:117485. [PMID: 34015517 DOI: 10.1016/j.jns.2021.117485] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
42 Khorkova O, Hsiao J, Wahlestedt C. Nucleic Acid-Based Therapeutics in Orphan Neurological Disorders: Recent Developments. Front Mol Biosci 2021;8:643681. [PMID: 33996898 DOI: 10.3389/fmolb.2021.643681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
43 Bianchi L, Sframeli M, Vantaggiato L, Vita GL, Ciranni A, Polito F, Oteri R, Gitto E, Di Giuseppe F, Angelucci S, Versaci A, Messina S, Vita G, Bini L, Aguennouz M. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients. Int J Mol Sci 2021;22:4329. [PMID: 33919289 DOI: 10.3390/ijms22094329] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Tang Z, Zhao J, Pearson ZJ, Boskovic ZV, Wang J. RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays. Molecules 2021;26:2263. [PMID: 33919699 DOI: 10.3390/molecules26082263] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
45 Li Z, Li X, Shen J, Tan H, Rong T, Lin Y, Feng E, Chen Z, Jiao Y, Liu G, Zhang L, Vai Chan MT, Kei Wu WK. Bioinformatic analysis of SMN1-ACE/ACE2 interactions hinted at a potential protective effect of spinal muscular atrophy against COVID-19-induced lung injury. Brief Bioinform. 2021;22:1291-1296. [PMID: 33190150 DOI: 10.1093/bib/bbaa285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 AlRuthia Y, Almuaythir GS, H Alrasheed H, Alsharif WR, Temsah MH, Alsohime F, Sales I, Alwhaibi M, Bashiri FA. Proxy-Reported Quality of Life and Access to Nusinersen Among Patients with Spinal Muscular Atrophy in Saudi Arabia. Patient Prefer Adherence 2021;15:729-39. [PMID: 33880016 DOI: 10.2147/PPA.S305849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
47 Müller-felber W, Vill K, Schwartz O, Blaschek A, Nennstiel U, Schara U, Hoffmann GF, Gläser D, Becker M, Röschinger W, Bernert G, Klein A, Kölbel H. Neugeborenenscreening auf spinale Muskelatrophie. Monatsschr Kinderheilkd 2021. [DOI: 10.1007/s00112-021-01165-1] [Reference Citation Analysis]
48 Wei J, Takamatsu Y, Wada R, Fujita M, Ho G, Masliah E, Hashimoto M. Therapeutic Potential of αS Evolvability for Neuropathic Gaucher Disease. Biomolecules 2021;11:289. [PMID: 33672048 DOI: 10.3390/biom11020289] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
49 Tiziano FD, Tizzano EF. 25 years of the SMN genes: the Copernican revolution of spinal muscular atrophy. Acta Myol 2020;39:336-44. [PMID: 33458589 DOI: 10.36185/2532-1900-037] [Reference Citation Analysis]
50 Volpe JJ. Infantile spinal muscular atrophy - the potential for cure of a fatal disease. J Neonatal Perinatal Med 2021;14:153-7. [PMID: 33459670 DOI: 10.3233/NPM-200680] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
51 Voskobiynyk Y, Battu G, Felker SA, Cochran JN, Newton MP, Lambert LJ, Kesterson RA, Myers RM, Cooper GM, Roberson ED, Barsh GS. Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy. PLoS Genet 2021;17:e1009195. [PMID: 33411788 DOI: 10.1371/journal.pgen.1009195] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
52 Wirth B. Spinal Muscular Atrophy: In the Challenge Lies a Solution. Trends Neurosci 2021;44:306-22. [PMID: 33423791 DOI: 10.1016/j.tins.2020.11.009] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 20.0] [Reference Citation Analysis]
53 Hein L, Seifert R. Neue Arzneimittel 2020. Arzneiverordnungs-Report 2021 2021. [DOI: 10.1007/978-3-662-63825-5_2] [Reference Citation Analysis]
54 Chiu W, Hsun YH, Chang KJ, Yarmishyn AA, Hsiao YJ, Chien Y, Chien CS, Ma C, Yang YP, Tsai PH, Chiou SH, Lin TY, Cheng HM. Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases. Int J Mol Sci 2020;21:E9589. [PMID: 33339321 DOI: 10.3390/ijms21249589] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
55 Flotats-Bastardas M, Hahn A. New Therapeutics Options for Pediatric Neuromuscular Disorders. Front Pediatr 2020;8:583877. [PMID: 33330280 DOI: 10.3389/fped.2020.583877] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Paul GR, Gushue C, Kotha K, Shell R. The respiratory impact of novel therapies for spinal muscular atrophy. Pediatr Pulmonol 2021;56:721-8. [PMID: 33098622 DOI: 10.1002/ppul.25135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
57 Mathews KD, Iannaccone ST. Combination molecular therapies for spinal muscular atrophy: How much is enough? Muscle Nerve 2021;63:279-81. [PMID: 33118639 DOI: 10.1002/mus.27109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]